OKYO Pharma Limited Return on Equity

OKYO Pharma Limited (OKYO) currently reports a ROE of -88.99%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore OKYO Pharma Limited's ROE history and peer comparisons.

OKYO Pharma Limited's ROE of -88.99% is lower than the Healthcare sector average of 29.33%. That is roughly 403.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but OKYO Pharma Limited's current -88.99% should be judged against Healthcare norms (sector average: 29.33%) and against OKYO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -88.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for OKYO Pharma Limited, and consider following OKYO for alerts when major investors trade the stock.

OKYO Pharma Limited is classified in the Healthcare sector. On ROE, it currently shows -88.99% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OKYO with unrelated industries.